In those with advanced oxyntic atrophy shown by endoscopy with biopsies, or markers of oxyntic atrophy, such as elevated gastrin or low pepsinogen I [130], or demonstration of anacidity in combination with negative H. pylori serology, the logical attitude would be to prevent continuous gastrin stimulation by using the gastrin antagonist netazepide [128]. The gene discussed is GAST; the disease is Atrophy.